Novo Nordisk's (NVO) stock jumped more than 7% in pre-market trading Wednesday after beating Wall Street's profit estimates for the first quarter, and despite a slight cut to its sales forecast for the year.

Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share with 99 cents per share compared to estimates of 94 cents per share.

Sales of the company's blockbuster GLP-1 drugs, up 13% year-over-year, drove the quarter's results, despite a slight slowdown in weight loss sales.BAGSVæRD, DENMARK - 2025/03/27: A view of the logo of Novo Nordisk A/S at the headquarters in Bagsværd. Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. (Photo by Kristian Tuxen Ladegaard Berg/SOPA Images/LightRocket via Getty Images)·SOPA Images via Getty Images

Wegovy sales came in at $2.6 million, 7% below Wall Street's consensus, meanwhile Ozempic sales for the quarter were $4.9 million, or about 3% ahead of estimates.

Pressure on Wegovy sales could ease as the company sees slowing of compounded copies of the weight loss drug, after the FDA confirmed the shortage was over earlier this year. The drug has been losing market share to competitor Eli Lilly's (LLY) Zepbound in the U.S.

Still, CEO Lars Fruergaard Jørgensen said on an earnings call Wednesday morning that despite that slowdown, Novo Nordisk holds about 72% of the global obesity and diabetes GLP-1 market share.

NYSE - Delayed Quote•USD

(NVO)

Follow  View Quote Details

66.29

-

(-4.09%)

At close: May 6 at 4:00:02 PM EDT  Advanced Chart

"We have launched Wegovy in 25 countries, including three in that last month, reflecting greater supply availability," Jørgensen said.

Novo has engaged in a number of deals in the past month that would increase access to the drug in the U.S., including relationships with telehealth platforms like Hims & Hers (HIMS), and being named the preferred drug on CVS (CVS) formulary. The latter sent Lilly's stock diving last week.

Jørgensen said the CVS deal would only serve a fraction of the market and was "not really about gaining a share short-term."

Novo cut sales guidance for the year by 3%, now estimating 13%-21%, compared to previous guidance of 16% to 24%.

Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, care services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem.

For the latest earnings reports and analysis, earnings whispers and expectations, and company earnings news, click here

Read the latest financial and business news from Yahoo Finance

View Comments